Epidemiologic Characteristics of Patients with Inflammatory Bowel Disease in Kermanshah, Iran

Mehdi Zobeiri, Homayoon Bashiri, Lotfollah Askari, Ali Asghar Keshavars, Ramin Tavvafzadeh, Kiomars Fatahi, Farid Najafi

INTRODUCTION

Inflammatory bowel disease (IBD) includes two distinct entities; ulcerative colitis (UC) and Crohn’s disease (CD) with chronic, relapsing, multi-factorial inflammatory disorder of the gastrointestinal tract but with different pathological and clinical characteristics.

CONCLUSION

The demographic and clinical manifestations of IBD are usually the same as other developing countries; however, the rarity of CD is eminent. Although the accurate epidemiological characteristic of IBD in Iran is still obscure, it is not a rare disease as previously thought and it seems that gradual reception of a western lifestyle may be linked to the ongoing rise in IBD.

KEYWORDS:
Inflammatory bowel disease, Epidemiology, Kermanshah, Iran.

Please cite this paper as:
Zobeiri M, Bashiri H, Askari L, Keshavars AA, Tavvafzadeh R, Fatahi K, Najafi F. Epidemiologic Characteristics of Patients with Inflammatory Bowel Disease in Kermanshah, Iran. Middle East J Dig Dis 2017;9:164-169. DOI: 10.15171/mejdd.2017.68.
environmental agents are involved in the pathogenesis. More than 160 susceptibility loci/genes with significant association with IBD have been identified.

More than 100 identified genes of IBD susceptibility were not adequate to clarify the high rate of IBD in developed and developing countries.

IBD has higher incidence in the northern parts of the world and between whites than in non-white populations. Various geographical differences and time trends in the occurrence rates of IBD in a given region may create insights into conceivable etiological factors. Geographical location plays a potential role in IBD development and in phenotype and course of the disease. It is important that only finite data on the IBD epidemiology exist in underdeveloped countries. Recently a nationwide study showed increasing incidence and prevalence of IBD in Iran. Sporadic studies of IBD in Iran are mainly due to the lack of a public registration. We aimed to define the demographic and clinical characteristics of patients with IBD who had been visited in our university-based centers during a 1-year period. These data elucidate the profile differences of Iranian patients with IBD in comparison with other countries and may provide insight into the conceivable etiological agents.

MATERIALS AND METHODS

In this study, we collected the data of all 156 patients with IBD, who were visited during one-year period from 2014 to 2015 in the Gastroenterohepatology clinics of university-affiliated centers of Kermanshah province, west of Iran. The data were gathered using specially designed questionnaires containing the demographic data of the patients, signs and symptoms at the onset of the disease, date of onset, time interval between the disease onset and the time of diagnosis, and information about other clinical course. After obtaining informed consents the questionnaires were completed for all the patients by a trained assistant. IBD was diagnosed with histological, clinical, endoscopic, and radiological data described by Lenard-jones.

Our project was approved by institutional Ethics Committee. Analysis of data was performed using descriptive methods with SPSS software version 16. (Inc. Chicago, Il.)

RESULTS

Overall 156 patients were registered. Of them 154 patients had UC and 3 patients had CD. The mean age of the patients with UC at diagnosis was 31.02 ± 12.34 (range: 17 - 80) years with most common age group of 25 - 35 years (figure 1) and slight female predominance (51.9%, table 1). More urban patients were registered (90.4 %) and 57% had high school or upper education (table 1). Positive family history of the disease was in 25.6% and 66.6% had four or more family members. Furthermore, 51.9% had left sided colitis and 40.4% had pancolitis (table 2) with bloody diarrhea (79.5%) and
abdominal pain (68.6%) as the most common manifestations (table 3).

Musculoskeletal complaint was the most common extraintestinal manifestation (table 4). 36.5% had other autoimmune diseases, multiple flare with average of 2 in year was seen in 46.8%, most commonly due to drug discontinuation (26.28%). Hospital admission was reported in 34.6%. History of contraceptive pill use was in 38.8% of the female patients with an average of 6 years ingestion. Pregnancy was seen in 45% with 81.4% before disease involvement. 15.4% had surgical operations related to the disease and 18.8% were smokers with 16 packs per year smoking. Average time of breast feeding was 21 months. The disease onset show similar occurrence in four seasons (figure 2).

**DISCUSSION**

We present a comprehensive description of IBD in west of Iran, which will serve as an essential resource for further studies. IBD appears to be emerging as a global disease with significant and continuing increase in the entire world.\(^9\) Westernized nations have the highest incidence and prevalence of IBD. Westernization and industrialization of Asian countries like Iran with consideration of some environmental risk factors linked to the increase of the incidence and prevalence of IBD.\(^4\)9,10 However awareness of the disease and availability of diagnostic techniques may contribute.

Considerable differences were detected in the incidence of IBD across different geographical regions and over time.\(^9\) In most of these areas as in this study CD remains rare.\(^4\) It can be due to under diagnosis of CD. With emergence of IBD in developing countries, observations show the appearance of CD followed by UC.\(^11\) IBD is one of the gastrointestinal diseases with the most financial implication and no medical cure, so it requires a lifetime management.\(^12\) As shown here IBD involved individuals in the most productive ages with long-term financial burden on the patients, health care system, and society.\(^13\) Recently two large studies showed the rising prevalence of IBD in Iran.\(^7,14\) Dynamic occurrence and variations in the incidence and prevalence of IBD even during times not only emphasize the role of environmental factors in disease presentation and etiology but also prepare valuable information about the burden of the disease to be utilized by policy makers, funding agencies, and insurance and pharmaceutical companies.\(^15\) Spectrum of environmental factors differ from the mode of childbirth, breastfeeding, and antibiotic exposure in infancy in early life time to smoking, major stress, diet, and lifestyle later in adulthood.\(^15\) The prevalence of smoking was similar to UC smoking pattern in other study, which is much less than CD.\(^16\) However most of Iranian patients with IBD did not have smoking history.\(^17\) Low dietary fiber, high

---

**Table 3:** Primary manifestations of patients with IBD

| Manifestation          | Percentage |
|------------------------|------------|
| Bloody Diarrhea         | 79.9%      |
| Abdominal pain          | 71.4%      |
| Tenesmus                | 61%        |
| Weight loss             | 61%        |
| Musculoskeletal pain    | 33.1%      |
| Constipation            | 21.4%      |
| Diarrhea                | 14.9%      |
| Aphthous stomatitis     | 14.3%      |
| Red eye                 | 11.7       |
| Skin rash               | 9.1%       |
| Icter                   | 7.8%       |

**Table 4:** Frequency of extraintestinal manifestations of patients with IBD

| Manifestation          | Percentage |
|------------------------|------------|
| Musculoskeletal        | 51.9%      |
| Eye involvement         | 27.9%      |
| Skin involvement        | 22.7%      |
| Liver & Biliary         | 11%        |

---

**Fig.2:** Seasonal variation in the onset of IBD
saturated fats, depression, disturbed sleep, and low level of vitamin D have been related to IBD occurrence. Interventions for modifying these risk factors are among important unmet needs.\textsuperscript{15} Although IBD may occur at any age, the maximum age of onset is 15 to 30 years. In this study the mean age of diagnosis was 31 years, which was similar to other studies in Iran and other Asian countries without the second smaller peak that is usually observed in later decades in developed countries.\textsuperscript{18,19,20} In this survey patient aged less than 17 years were not detected although near 10% of the disease occur in children younger than 18 years.\textsuperscript{21} This study showed a slight female dominance in UC, which is in contrast to equal sex distribution in other Asian countries.\textsuperscript{22,23} As shows here IBD occurs more commonly in urban versus rural regions.\textsuperscript{24,25} The place of residence may also affect the phenotype and clinical course of the disease.\textsuperscript{26} Family history of the disease, which is greater among pediatric-onset UC and is with more disease severity, was detected in 25.6% of the patients similar to other parts of Asia and more than the results reported by Moller and colleagues in Europe.\textsuperscript{27,28} Bloody diarrhea was the most common presentations like another study at the disease onset.\textsuperscript{29} Most of the patients had left colon involvement so higher frequency of abdominal pain could be due to the presence of concomitant irritable bowel syndrome.

Extra-intestinal manifestations have a higher frequency in Iran than other Asian countries.\textsuperscript{17} As in other studies musculoskeletal manifestations are the most prevalent extra-intestinal manifestations but the percentage of affected patients was higher.\textsuperscript{29,30,31} It has been suggested that with the rising of IBD extension the risk of peripheral arthritis increases.\textsuperscript{32} Higher incidence of the disease extension correlates with higher musculoskeletal manifestations. Along with most studies conducted in Iran and Asian countries, majority of patient presented with left sided colitis.\textsuperscript{29,31,33,34} But study results in Singapore, Thailand, and Netherland showed a higher rate of pancolitis among the patients with UC.\textsuperscript{35,36,37}

No particular relation between the onset of the disease and the seasons was detected. Similar finding in a study conducted in Netherland and another study in Fars province, south of Iran was detected.\textsuperscript{29,36,37} But clinical onset of UC in Japan was significantly more common in winter and spring.\textsuperscript{38} However significant increase in the onset of UC (but not CD), during December was reported from Norway.\textsuperscript{39} Most common cause of disease flare was non-adherence to medical therapy. In a study conducted in Italy, 17.4% of the patients with IBD, especially young women who were followed up by general practitioners showed non-adherence to medical therapy but management by gastroenterologists associated with greater adherence to medical therapy.\textsuperscript{40} In the present study, 34.6% of the patients required hospital admission during the course of the disease, which is similar to a Chilean study.\textsuperscript{29} The risk of hospital admission increased with the disease extension, and the necessity for steroids and anti-TNF administration.\textsuperscript{41}

Average twice flare in a year in near half of the patient, mostly because of drug discontinuation needed further attention but infection with \textit{C. difficile}, which has similar presentations and can be a trigger for IBD flare has not been evaluated. These data can clarify the general characteristics of patients with IBD and improve management options.

The national IBD registry requires disease information which collected by accurately defined clinical questions. Scattered studies can show disease diversity and can be used as a base for observation of possible changes in disease pattern.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Vice Chancellery for Research and Technology, Kermanshah University of Medical Sciences.

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

REFERENCES

1. Pierik M, Yang H, Barmada MM, Cavanaugh JA, Annese V, Brant SR, et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. \textit{Inflamm Bowel Dis} 2005;11:1-7. doi: 10.1097/00054725-200501000-00001.

2. Wells AD, McMillan I, Price AB, Ritchie JK, Nicholls RJ. Natural history of indeterminate colitis. \textit{Br J Surg} 1991;78:179-81. doi: 10.1002/bjs.1800780214.

3. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. \textit{Gastroenterology} 2011;140:1704-12. doi: 10.1053/j.gastro.2011.02.046.
Epidemiologic Characteristics of Patients with IBD

4. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004;126: 1504-17. doi: 10.1053/j.gastro.2004.01.063.

5. Whelan G. Epidemiology of inflammatory bowel disease. *Med Clin North Am* 1990;74:1-12. doi: 10.1016/S0025-7125(16)30581-8.

6. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. *Clin Epidemiol* 2013;5:237–47. doi:10.2147/CLEPS33961.

7. Malekzadeh MM, Vahedi H, Gohari K, Mehdi pour P, Sepanlou SG, Ebrahim i Daryani N, et al. Emerging Epidemiology of Inflammatory Bowel Disease in a Middle Income Country: A Nation-wide Study from Iran. *Arch Iran Med* 2016;19:2–15.

8. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1989;242:2-6. doi:10.3109/003655298091933.

9. Molodecky NA, Soon IS, Rabi DM,Ghali WA, Ferris M, Chernoff G, et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. *Gastroenterology* 2012;142:46-54. doi: 10.1053/j.gastro.2011.10.001.

10. Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus Jr EV, Tysk C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. *Gut* 2013;62:630-64. doi:10.1136/gutjnl-2012-303661.

11. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. *Gut* 2008;57:1185-91. doi: 10.1136/gut.2007.122143.

12. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofo ldANJH, Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. *Dig Dis Sci* 2012;57:3080-91. doi:10.1007/s10620-012-2289-y.

13. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The cost of Crohn’s disease in the United States and other Western countries: a systematic review. *Curr Med Res Opin* 2008;24:319-28. doi:10.1185/030079908X260790.

14. Shayesteh AA, Saberifirozi M, Abedian S, Sebghatolahi V. Epidemiological, Demographic, and Colonic Extension of Ulcerative Colitis in Iran: A Systematic Review. *Middle East J Dig Dis* 2013;5:29-36.

15. AnanthakrishnanAN. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol* 2015;12:205-17. doi:10.1038/nrgastro.2015.34.

16. Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Titikci A, Par lakE, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. *J Clin Gastroenterol* 2009;43:51-7. doi: 10.1097/MCG.0b013e28181574636.

17. Safarpour AR, Hosseini SV, Mehrabani D. Epidemiology of inflammatory bowel diseases in Iran and Asia; a mini review. *Iran J Med Sci* 2013;38:140-9.

18. Aghazadeh R, Zali MR, Bahari A, Amin K, Gha ha ghaie F, Firouzi F. Inflammatory bowel disease in Iran: A review of 457 cases. *J Gastroenterol Hepatol* 2005;20:1691-95. doi:10.1111/j.1440-1746.2005.03905.x.

19. Darakhsan F, Khoj eini EV, Balai H, Naderi N, Firouzi F, Farnood A, et al. Epidemiology of Inflammatory Bowel Disease in Iran: A review of 803 cases. *Gastroenterol Hepatol Bed Bench* 2008;1:19-24.

20. Loftus EV, Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. *Gastroenterology Clin North Am* 2002;31:1-20.

21. Griffiths AM. Specificities of inflammatory bowel disease in childhood. *Best Pract Res Clin Gastroenterol* 2004;18:509-23. doi: 10.1016/j.bpcg.2004.01.002.

22. Yoshida Y, Murata Y. Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. *Med Clin North Am* 1990;74:67-90. doi:10.1016/S0025-7125(16)30887-9.

23. Duph are H, Misra SC, Patnaik PK, Mathur M, Tandon RK. Spectrum of ulcerative colitis in north India. *J Clin Gastroenterol* 1994;18:23-6.

24. Klement E, Lysy J, Hoshen M, Avitan M, Goldin E, Israeli E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study Hygiene and Inflammatory Bowel Disease. *Am J Gastroenterol* 2008;103:1775-82. doi: 10.1111/j.1572-0241.2008.01905.x.

25. Soon IS, Molodecky NA, Rabi DM, Ghali WA, Barkema HW, Kaplan GG. The relationship between urban environment and the inflammatorybowel diseases: a systematic review and meta-analysis. *BMC Gastroenterol* 2012;12:51. doi:10.1186/1471-230X-12-51.

26. Carpio D, Barreiro-de Acosta M, Echarri A, Pereira S, Castro J, Ferreiro R, et al. Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: a cross-sectional study. *Eur J Gastroenterol Hepatol* 2015;27:1030-7. doi: 10.1097/MEG.0000000000000395.

27. Kuwahara E, Asakura K, Nishi wak i Y, Inoue N, Watanabe M, Hibi T, et al. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. *J Gastroenterol* 2012;47:961-8. doi:10.1007/s00535-012-0558-3.

28. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. *Am J Gastroenterol* 2015;110:564-71. doi:10.1038/ajg.2015.50.

29. Taghavi SA, Safarpour AR, Hosseini SV, Noroozi H, Safarpour M, Rahimikazerouri S. Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A review of 740 patients in Fars province, Southern Iran. *Ann Colorectal Res* 2013;1:17-22. doi: 10.17795/acr-11477.

30. Simian D, Fluxá D, Flores L, Lubaszker J, Ibáñez P, Figueroa C, et al. Inflammatorybowel disease: A descrip-
tive study of 716 local Chilean patients. *World J Gastroenterol* 2016; **22**:5267-75. doi: 10.3748/wjg.v22.i22.5267.

31. Derakhshan F, Naderi N, Farnood A, Firouzi F, Habibi M, Rezvany MR, et al. Frequency of three common mutations of CARD15/ NOD2 gene in Iranian IBD patients. *Indian J Gastroenterol* 2008; **27**:8-11.

32. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. *World J Gastroenterol* 2006; **12**:4819-31. doi:10.3748/wjg.v12.i30.4819.

33. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. *World J Gastroenterol* 2002; **8**:158-61. doi: 10.3748/wjg.v8.i1.158.

34. Yang SK, Hong WS, Min YI, Kim HY, Yoo JY, Rhee PL, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. *J Gastroenterol Hepatol* 2000; **15**:1037-42. doi: 10.1046/j.1440-1746.2000.02252.x.

35. Ling KL, Ooi CJ, Luman W, Cheong WK, Choenn FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. *J Clin Gastroenterol* 2002; **35**:144-8.

36. Rerknimitr R, Chalapipat O, Kongkam P, Mb PK. Clinical characteristics of inflammatory bowel disease in Thailand: a 16 years review. *J Med Assoc Thai* 2005; **88**Suppl 4:S129-33.

37. Romberg-Camps MJ, Hesselink-van de Kruijf MA, Schouten LJ, Dagnelie PC, Limonard CB, Kester AD, et al. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991-2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. *J Crohns Colitis* 2009; **3**:115-24. doi: 10.1016/j.crohns.2008.12.002.

38. Koido S, Ohkusa T, Saito H, Yokoyama T, Shibuya T, Sakamoto N, et al. Seasonal variations in the onset of ulcerative colitis in Japan. *World J Gastroenterol* 2013; **19**:9063-8. doi:10.3748/wjg.v19.i47.9063.

39. Moum B, Aadland E, Ekbom A, Vatn MH. Seasonal variations in the onset of ulcerative colitis. *Gut* 1996; **38**:376-8. doi: 10.1136/gut.38.3.376.

40. Zelante A, De Giorgi A, Borgoni R, Trevisani L, Gallegani M. Adherence to medical treatment in inflammatory bowel disease patients. *Minerva Gastroenterol Dietol* 2014; **60**:269-74.

41. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Pare R, et al. Long-term evolution of disease behavior of Crohn’s disease. *Inflamm Bowel Dis* 2002; **8**:244-250.